TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB
TAK-279-CD-2001
Phase 2 small_molecule active
Quick answer
TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB for Moderately to Severely Active Crohn's Disease is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Moderately to Severely Active Crohn's Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active